Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesZentalis Pharmaceuticals Llc

Zentalis Pharmaceuticals Llc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.77 USD 0.05 ( 2.91%)
Last update at 2026-11-09T17:58:00Z
VOLUME
570641
Market Cap
296.32M

Momentum Score

…

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.66
Low
1.79
High
52 Week Price Range
1.21
Low
6.95
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Zentalis Pharmaceuticals LLC is a clinical-stage biopharmaceutical company developing small-molecule oncology therapies across a pipeline of targeted candidates. Long-term growth drivers include advancement of clinical programs, regulatory approvals, and potential strategic partnerships that could support commercialization. Investors may find upside in positive trial readouts and a targeted pipeline addressing multiple cancer indications.
Main risks are high clinical and regulatory failure probability, absence of product revenue and recurring financing needs, and competition from larger oncology companies.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.72
Dividend Yield
-
Revenue TTM
26.86M
Revenue Per Share
0.37
Gross Profit TTM
26.86M
Debt / Equity
0.18
ROE
-66.75%
Net Debt
3.58M
ROCE
-57.45%
Diluted EPS TTM
-1.75

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -136.62M -165.69M -292.91M -221.30M -164.56M
Minority interest 0.00M 0.03M 0.10M -0.31M -7.37M
Net income -137.06M -165.84M -292.19M -220.83M -164.26M
Selling general administrative 37.72M 87.11M 59.40M 54.55M 40.94M
Selling and marketing expenses - - 1.39M - -
Gross profit -0.74M 67.42M -1.39M - -
Reconciled depreciation 0.74M 1.29M 1.41M 1.43M 0.54M
Ebit -145.01M -187.46M -248.99M -227.29M -216.54M
Ebitda -144.27M -186.17M -247.60M -233.27M -268.52M
Depreciation and amortization 0.74M 1.29M 1.39M -5.99M -51.98M
Non operating income net other - - - -16.28M 49.75M
Operating income -152.81M -191.19M -299.51M -227.29M -216.54M
Other operating expenses 152.81M 258.62M 299.51M 227.29M 216.54M
Interest expense - - - 2.58M 110.05M
Tax provision 0.44M 0.18M -0.83M -0.47M -0.30M
Income tax expense 0.44M 0.18M -0.60M -0.47M -0.30M
Total revenue 0.00M 67.42M 0.00M 0.00M 0.00M
Total operating expenses 152.81M 258.62M 299.51M 227.29M 216.54M
Cost of revenue 0.74M 1.29M 1.39M - -
Total other income expense net 16.19M 25.50M 6.60M 5.99M 51.98M
Net income from continuing ops -137.06M -165.87M -286.35M -220.83M -164.26M
Net income applicable to common shares - - - -236.81M -158.72M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 288.97M 430.34M 562.03M 539.31M 454.51M
Other current assets 5.37M 9.98M 13.80M 14.56M 10.88M
Total liab 72.76M 93.15M 124.64M 105.29M 90.03M
Total stockholder equity 216.20M 337.19M 437.28M 434.02M 364.48M
Other current liab 25.48M 42.22M 51.54M 45.40M 30.90M
Common stock 0.07M 0.07M 0.07M 0.06M 0.04M
Capital stock 0.07M 0.07M 0.07M 0.06M 0.04M
Retained earnings -1191.45M -1054.39M -888.56M -596.37M -359.56M
Other liab - - - 3.47M 1.62M
Good will - 0.00M 3.74M 3.74M 3.74M
Other assets - - - 12.35M 9.67M
Cash 35.99M 33.90M 28.04M 43.07M 59.71M
Total current liabilities 36.56M 52.73M 69.37M 56.65M 43.94M
Current deferred revenue - - 0.28M - -
Net debt 3.58M 8.75M 17.73M 2.10M -13.80M
Short term debt 3.87M 3.07M 2.62M - 1.45M
Short long term debt total 39.58M 42.65M 45.77M 45.17M 45.91M
Other stockholder equity 1407.39M 1390.95M 1323.58M 1031.68M 724.12M
Property plant equipment - - - 7.71M 8.15M
Total current assets 253.19M 386.07M 496.72M 451.93M 350.77M
Long term investments - - 0.00M 21.21M 37.49M
Net tangible assets - - - 433.80M 360.22M
Short term investments 209.90M 337.18M 454.88M 394.30M 280.17M
Net receivables 1.93M 5.00M - - 4.44M
Inventory - - - - -4.44M
Accounts payable 7.21M 7.44M 14.93M 11.25M 11.59M
Noncontrolling interest in consolidated entity - - - 0.22M 0.53M
Accumulated other comprehensive income 0.20M 0.56M 2.19M -1.35M -0.12M
Common stock total equity - - - 0.06M 0.04M
Retained earnings total equity - - - -596.37M -359.56M
Non currrent assets other 6.74M 4.42M 6.82M 12.35M 2.63M
Non current assets total 35.78M 44.27M 65.31M 87.38M 103.74M
Capital lease obligations 35.70M 39.58M 43.15M 45.17M 45.91M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 130.93M 176.56M -14.29M -111.63M 2.31M
Change to liabilities - - - 15.53M 13.92M
Total cashflows from investing activities 131.62M 176.56M -44.46M -114.18M -18.11M
Total cash from financing activities -4.28M 0.11M 237.30M 261.04M 178.52M
Change to operating activities - - - -2.27M 2.23M
Net income -137.06M -165.87M -292.19M -237.11M -166.09M
Change in cash 2.09M 5.81M -14.98M -16.89M 6.31M
Begin period cash flow 36.53M 30.72M 45.70M 62.58M 56.27M
End period cash flow 38.62M 36.53M 30.72M 45.70M 62.58M
Total cash from operating activities -125.25M -170.86M -207.82M -163.75M -154.09M
Issuance of capital stock 5.69M 0.35M 287.04M 261.04M 179.67M
Depreciation 0.74M 1.29M 1.39M 1.43M 0.54M
Other cashflows from investing activities 0.70M 0.07M - - -14.32M
Change to inventory - - - - 0.88M
Change to account receivables 5.00M -5.00M 0.00M - 0.41M
Sale purchase of stock -9.98M 0.00M 0.00M 261.04M 179.67M
Other cashflows from financing activities - -0.24M -44.46M -114.18M -1.15M
Change to netincome - - - 62.41M 46.38M
Capital expenditures 0.00M 0.22M 0.58M 2.55M 6.11M
Change receivables - - - - 0.41M
Cash flows other operating - - - -2.27M -50.16M
Cash and cash equivalents changes - - - -16.89M 6.31M
Change in working capital -9.12M -16.54M 5.86M 13.25M 16.56M
Stock based compensation 20.72M 67.27M 54.82M 46.84M 35.74M
Other non cash items -0.53M -57.01M 23.15M 12.61M -38.38M
Free cash flow -125.25M -171.08M -208.41M -166.30M -160.20M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ZNTL
Zentalis Pharmaceuticals Llc		 0.05
2.91%		 1.77 - - 7.13 2.31 7.77 -2.31
NVO
Novo Nordisk A/S		 1.03
2.56%		 41.34 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.49
0.27%		 548.58 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 18.16
2.01%		 922.51 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Zentalis Pharmaceuticals Llc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.

10275 Science Center Dr., San Diego, CA, United States, 92121

858 263 4333

https://zentalis.com

106

Name Title Year Born
Dr. Kimberly Lynn Blackwell M.D. CEO & Director 1969
Mr. Cameron S. Gallagher M.B.A. Co-Founder, Pres & Director 1970
Dr. Kevin D. Bunker Ph.D. Co-Founder & Chief Scientific Officer 1972
Ms. Melissa B. Epperly M.B.A. CFO & Treasurer 1978
Adam Levy Sr. VP of Investor Relations NA
Ms. Andrea Paul J.D. Gen. Counsel & Corp. Sec. 1981
Dr. Meena Rao Ph.D. Sr. VP of Regulatory Affairs & Quality Assurance NA
Dr. Carrie Brownstein M.D. Chief Medical Officer 1970
Dr. Mark Lackner Ph.D. Chief Translational Officer & Head of Biomarker Strategy 1967
Dr. Kimberly Lynn Blackwell M.D. CEO & Director 1970

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…